Epithelioid
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read MoreAnalysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
Oncology 2025 January 24 [Link] Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM)…
Read MoreSurgical indications for pleurectomy/decortication in pleural mesothelioma based on the newly revised 9th edition of the tumour-node-metastasis classification
Interdisciplinary Cardiovascular and Thoracic Surgery 2024 December 25 [Link] Masatoshi Kanayama, Masaru Takenaka, Takehiko Manabe, Katsuma Yoshimatsu, Rintaro Oyama, Hiroki Matsumiya, Masataka Mori, Koji Kuroda, Fumihiro Tanaka Abstract Objectives: The MARS2 trial questioned the efficacy of curative intent surgery for pleural mesothelioma (PM), while real-world clinical data from Japan suggest a favourable prognosis in surgical…
Read MoreParadoxical Improvement in Malignant Pleural Mesothelioma Outcomes Following Delayed Treatment Initiation
Cancers 2024 November 7 [Link] Ashwin Kulshrestha, Emanuela Taioli, Andrea Wolf, Raja Flores, Stephanie Tuminello Abstract Background/objectives: Time to treatment initiation (TTI) has been identified as a predictor of survival in many cancers, but its impact on malignant pleural mesothelioma (MPM) is unknown. This study investigates factors influencing TTI in MPM and its association with…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic Cardiovascular Surgical Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic and Cardiovascular Surgery Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs)…
Read MoreReal-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study
Asia-Pacific Journal of Clinical Oncology 2024 December [Link] Kar Ven Cavan Chow, Cassie Turner, Brett Hughes, Zarnie Lwin, Bryan Chan Abstract Aim: To evaluate the real-world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy. Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers…
Read MoreCharacteristics of long-term survivors with malignant pleural mesothelioma
The Annals of Thoracic Surgery 2024 October 22 [Link] Isabelle Opitz, Olivia Lauk, Raphael Werner, Alessandra Matter, Monika Hebeisen, Bianca Battilana, Hasan Batirel, Harvey Pass, Raja Flores, Andrea Wolf, Marc de Perrot, Mir Alireza Hoda, Walter Klepetko, Thomas Klikovits, Masaki Hashimoto, Seiki Hasegawa, William G Richards, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) is a…
Read MoreDouble immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report
Translational Lung Cancer Research 2024 September 30 [Link] Gaspard Naulleau, Isabelle Monnet, Gaëlle Rousseau-Bussac, Florent Vinas, Gilles Mangiapan, Laurence Jabot, Amel Boudjemaa, Christos Chouaïd, Jean-Bernard Auliac, Jean-Baptiste Assié Abstract Background: Use of immune checkpoint inhibitors (ICIs) is associated with new response types, such as hyperprogressive disease (HPD), whose definition is still being discussed. Some authors…
Read MoreEfficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Clinical Lung Cancer 2024 December [Link] Diego Enrico, Juan Elias Gomez, Danilo Aguirre, Natalia Soledad Tissera, Florencia Tsou, Carmen Pupareli, Delfina Peralta Tanco, Federico Waisberg, Andrés Rodríguez, Manglio Rizzo, Nicolás Minatta, Picon Rafael, Luis Basbus, Lorena Lupinacci, Diego Kaen, Mauro Ramos, Virginia Bluthgen, Nicolas Castagneris, María Pía Coppola, Alejandra Scocimarro, María Florencia Guerra, Aldo Perfetti,…
Read More